Business continuity and supply risks from COVID-19 and other infectious diseases
First written in FY2020. 9 of 14 entries say "Restated". Latest entry: FY2025-H1.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
- FY2025-H1RestatedAnnual report
「During the interim accounting period, no new business or other risks arose. In addition, there were no significant changes to the business and other risks described in the securities report for the previous fiscal year.」
We state that there have been no material changes to existing risks, including business continuity and supply risks arising from infectious diseases. - FY2024-Q3RestatedAnnual report
「During the cumulative third-quarter period, no new business or other risks arose. In addition, there were no significant changes to the business and other risks described in the securities report for the previous fiscal year.」
We state that there have been no material changes to existing risks, including business continuity and supply risks arising from infectious diseases. - FY2024-Q2RestatedAnnual report
「Restrictions on activities related to COVID-19 have been eased, and social and economic activity is recovering toward normalization.」
We described the easing of restrictions on activities related to the infectious disease and the recovery trend in social and economic activity, maintaining our previous view that the environment has eased. - FY2024-Q1SoftenedAnnual report
「Restrictions on activities related to COVID-19 have been eased, and social and economic activity is recovering toward normalization.」
We state that restrictions on activities related to the infectious disease have been eased and that social and economic activity is recovering toward normalization. - FY2023SoftenedAnnual report
「Although COVID-19's legal classification under the Infectious Diseases Act was downgraded in May 2023, we will continue our business activities based on appropriate measures and management.」
We described the downgrade in the legal classification of the infectious disease and stated that, although the external environment surrounding infectious-disease risk has eased from before, measures and management will continue. - FY2023-Q3RestatedAnnual report
「There have been no material changes to the assumptions described in the additional information section of the previous fiscal year's securities report, "Accounting estimates concerning the impact of the spread of COVID-19," including assumptions about the future spread and timing of containment of COVID-19.」
We state that there have been no material changes to the accounting assumptions concerning the future spread and timing of containment of COVID-19. - FY2023-Q2RestatedAnnual report
「There have been no material changes to the assumptions described in the additional information section of the previous fiscal year's securities report, "Accounting estimates concerning the impact of the spread of COVID-19," including assumptions about the future spread and timing of containment of COVID-19.」
We state that there have been no material changes to the accounting assumptions concerning the future spread and timing of containment of COVID-19. - FY2022WorsenedAnnual report
「We had assumed that the infectious disease would largely subside during the fiscal year ending March 2022 and that the economy would gradually recover thereafter. However, as of the end of the fiscal year, social and economic activity had not yet recovered. Although an accurate outlook remains difficult, we now assume that the infectious disease will largely subside during the fiscal year ending March 2023 and that the economy will gradually recover thereafter.」
We pushed back the assumed timing of the infectious disease's containment and economic recovery by 1 year, from the fiscal year ending March 2022 to the fiscal year ending March 2023, and described the prolonged impact. - FY2022-Q2RestatedAnnual report
「During the cumulative second-quarter period, no new business or other risks arose. In addition, there were no significant changes to the business and other risks described in the securities report for the previous fiscal year.」
We state that there have been no material changes to existing business and other risks, including business continuity and supply risks arising from infectious diseases. - FY2022-Q1RestatedAnnual report
「No new business or other risks arose during the cumulative first quarter. There were also no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
We state that there have been no material changes to existing business and other risks, including business continuity and supply risks arising from infectious diseases. - FY2021-Q3WorsenedAnnual report
「We had assumed that the infectious disease would largely subside during the fiscal year ending March 2021 and that the economy would gradually recover thereafter. However, as of the end of the third quarter accounting period, social and economic activity had not yet recovered. Although an accurate outlook remains difficult, we now assume that the infectious disease will largely subside during the fiscal year ending March 2022 and that the economy will gradually recover thereafter.」
We changed the assumed timing of the infectious disease's containment from the fiscal year ending March 2021 to the fiscal year ending March 2022 and stated that the recovery in social and economic activity had been delayed. - FY2021-Q2RestatedAnnual report
「During the cumulative second quarter, no new business or other risks arose. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year. We will continue to closely monitor the impact of COVID-19 on our business.」
We continue to monitor the impact of COVID-19 on the business and state that there are no new risks or material changes to existing risks. - FY2021-Q1RestatedAnnual report
「During the cumulative first quarter, no new business or other risks arose. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year. We will continue to closely monitor the impact of COVID-19 on our business.」
The company states that there are no new risks or material changes to existing risks, while continuing to monitor the impact of COVID-19. - FY2020First statedAnnual report
「In the event of an outbreak or spread of an infectious disease, including COVID-19, we will take measures to continue operating as a regional lifeline while prioritizing the safety of customers and employees. However, if infections occur in the regions or offices where we operate and disrupt business continuity, or if business partners suffer adverse effects due to human, physical or financial factors arising from an infectious disease, resulting in unstable product supplies or fluctuations in purchase prices, our business performance may be affected.」
We have identified as new key risks disruptions to business continuity caused by infections, human, physical and financial impacts on business partners, and fluctuations in product supplies and purchase prices.